Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana

Journal of the International AIDS Society

Volumn 21, Issue 5, 2018, Pages

  Ibrahim, Maryanne ^a,b,c   Maswabi, Kenneth ^c   Ajibola, Gbolahan ^c   Moyo, Sikhulile ^c   Hughes, Michael D ^c,d   Batlang, Oganne ^c   Sakoi, Maureen ^c   Auletta Young, Chloe ^d   Vaughan, Laura ^d   Lockman, Shahin ^c,e   Jean Philippe, Patrick ^f   Yu, Xu ^g   Lichterfeld, Matthias ^g   Kuritzkes, Daniel R ^e   Makhema, Joseph ^c   Shapiro, Roger L ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

children; HIV; mother to child transmission; paediatrics; vertical transmission; viral suppression

Indexed keywords

ADULT; BOTSWANA; DRIED BLOOD SPOT TESTING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; RISK; TRANSMISSION; VERTICAL TRANSMISSION;

ADULT; BOTSWANA; DRIED BLOOD SPOT TESTING; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK;

EID: 85057969692     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1002/JIA2.25111     Document Type: Article

References (20)

1. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. World Health Organization, 2010, Geneva. Available from: http://www. who.int/hiv/pub/paediatric/diagnosis/en/[cited: 2018 Apr 25].
2. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013;382: 1555–63.
3. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014;28:1015–20.
4. Sherman GG. HIV testing during the neonatal period. South Afr J HIV Med. 2015;16(1):3. https://doi.org/10.4102/hivmed.v16i1.362.
5. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014;210(10):1529–38. https://doi. org/10.1093/infdis/jiu297.
6. Botswana Prevention of Mother-to-Child Transmission Data, January December 2015 (C Petlo, personal communication, 2016).
7. Phiri NA, Lee HY, Chilenga L, Mtika C, Sinyiza F, Musopole O, et al. Early infant diagnosis and outcomes in HIV-exposed infants at a central and a district hospital Northern Malawi. Public Health Action. 2017;7:83–9.
8. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization Programme, 2016. Geneva, Switzerland. Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/[cited: 2018 Apr 25].
9. National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults. National Department of Health, South Africa, April 2015. Available from: https://aidsfree.usaid.gov/sites/default/files/tx_south-africa_pmtc t_2015.pdf. [cited: 2018 Mar 16]
10. Botswana Ministry of Health. Handbook of the Botswana 2016 Integrated HIV Clinical Care Guidelines. Available from: http://www.moh.gov.bw/guidelines. html. [cited 2018 Mar 16].
11. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
12. Roider J, Mbatha BP, Hlope D, Muenchhoff M, Sprenger K, Graza Y, et al. Initiation of ART within 24–48 hours of birth following in utero hiv infection: the Ucwaningo Lwabantwana Study. J Virus Erad 2016; 2(Suppl 2): 8–30.
13. Botswana Ministry of Health. Botswana National HIV & AIDS Treatment Guidelines. Gaborone, Botswana: Ministry of Health P/Bag 0038; 2012.
14. de Vincenzi I, Kesho Bora Study Group. Triple-antiretroviral (ARV) prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1 (MTCT): the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya, and South Africa. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town; July 19-22, 2009. Abstract LBPEC01.
15. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Team IBFPS. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375:1726–37.
16. Fowler MG, Mofenson LM, Taha TE. Antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2017;376:699–700.
17. Vital Statistics. Statistics Botswana. Available from: http://www.statsbots. org.bw/vital-statistics. Published August 2, 2016. [Cited 2017 Mar 16].
18. Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS. 2012;26:1483–90; 3495308.
19. Goulder PJ, Lewin SR, Leitman EM. Paediatric HIV infection: the potential for cure. Nat Rev Immunol. 2016;16:259–71.
20. Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. J Infect Dis. 2016;214:1319–28.